Control
Oct 14 2024 |
et al., Scientia Pharmaceutica, doi:10.3390/scipharm92040056 | Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial |
| RCT with 29 mild COVID-19 outpatients in Switzerland, showing no significant difference with methylene blue treatment. There was a trend towards faster viral clearance. There were no serious adverse events. The trial was discontinued earl.. | ||
Apr 16 2024 |
et al., ScienceOpen, doi:10.58647/DRUGARXIV.PR000010.v1 | Network-based multi-omics-disease-drug associations reveal drug repurposing candidates for COVID-19 disease phases |
| In silico study identifying potential drugs beneficial for COVID-19 by integrating transcriptomics, proteomics, metabolomics, lipidomics, and drug data. Authors explore interactions between drugs, molecular features, and disease severity... | ||
Dec 22 2023 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1297924 | Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2 |
| In silico study showing potential benefit of mebendazole and zinc against SARS-CoV-2 according to an AI platform, eVir, designed to identify repurposed oral therapies. The software pipeline analyzes drug impacts on protein-protein network.. | ||
May 29 2023 |
et al., Pharmaceuticals, doi:10.3390/ph16060799 | Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients |
| RCT 69 outpatients in Jordan, showing improved viral clearance and CRP with mebendazole. Authors note that mebendazole, like ivermectin, has been shown to have antiviral activity against multiple viruses. | ||
Dec 10 2022 |
et al., Advances in Virology, doi:10.1155/2022/3014686 | The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study |
| Retrospective 157 inpatients and 185 outpatients, showing improved recovery with mebendazole. For outpatients, the treatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable. The outp.. | ||
Dec 10 2022 |
et al., Advances in Virology, doi:10.1155/2022/3014686 | The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study |
| Retrospective 157 inpatients and 185 outpatients, showing improved recovery with mebendazole. For outpatients, the treatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable. The outp.. | ||